LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

Home・Listă Acțiuni・Sanofi

Sanofi

Închisă

53.25 0.72

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

53.19

Maxim

53.27

Indicatori cheie
By Trading Economics
Venit	1.7B 2.8B
Vânzări	2.8B 14B
P/E Medie Sector	30.71 104.138
EPS	2.25
Marjă de profit	19.884
EBITDA	2.2B 4.2B

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+22.02 upside

Statistici piață
By TradingEconomics
Capitalizare de piață	136B
Deschiderea anterioară	52.53
Închiderea anterioară	53.25

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

52.98 / 53.66 Suport & Rezistență

Sanofi Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

28 oct. 2024, 16:07 UTC

Achiziții, Fuziuni, Preluări

AbbVie to Acquire Aliada Therapeutics for $1.4 Billion -- Update

25 oct. 2024, 05:44 UTC

Câștiguri

Sanofi Profit, Sales Beat Estimates

21 oct. 2024, 08:29 UTC

Achiziții, Fuziuni, Preluări

Sanofi Enters Exclusive Talks With CD&R Over Consumer Business Stake Sale -- 2nd Update

21 oct. 2024, 06:31 UTC

Achiziții, Fuziuni, Preluări

Sanofi Enters Exclusive Talks With CD&R Over Opella Stake Sale -- Update

21 oct. 2024, 06:13 UTC

Achiziții, Fuziuni, Preluări

Sanofi Expects Faster Earnings Growth Without Opella

21 oct. 2024, 06:02 UTC

Achiziții, Fuziuni, Preluări

Sanofi Enters Exclusive Talks With CD&R Over Opella Stake Sale

17 oct. 2024, 16:21 UTC

Achiziții, Fuziuni, Preluări

PAI Partners Submits Improved Bid on Sanofi's Consumer Unit

16 oct. 2024, 16:03 UTC

Achiziții, Fuziuni, Preluări

Sanofi in Talks With French Government to Address Concerns on Opella Deal

11 oct. 2024, 11:33 UTC

Achiziții, Fuziuni, Preluări

Sanofi in Talks to Sell Controlling Stake in Consumer Health Arm to CD&R -- 2nd Update

25 oct. 2024, 20:25 UTC

Câștiguri

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

25 oct. 2024, 13:12 UTC

Câștiguri

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

25 oct. 2024, 07:00 UTC

Market Talk

Câștiguri

Achiziții, Fuziuni, Preluări

Sanofi's 3Q Results Show Solid Vaccine Performance -- Market Talk

25 oct. 2024, 05:30 UTC

Câștiguri

Sanofi 3Q Adj EPS EUR2.86

25 oct. 2024, 05:30 UTC

Câștiguri

Sanofi 3Q FCF EUR3.33B

25 oct. 2024, 05:30 UTC

Câștiguri

Analysts Saw Sanofi 3Q Business Operating Income at EUR4.03B

25 oct. 2024, 05:30 UTC

Câștiguri

Sanofi 3Q Business Net Profit EUR3.59B

25 oct. 2024, 05:30 UTC

Câștiguri

Sanofi 3Q Sales EUR13.44B

25 oct. 2024, 05:30 UTC

Câștiguri

Analysts Saw Sanofi 3Q Sales at EUR12.63B

25 oct. 2024, 05:30 UTC

Câștiguri

Sanofi 3Q Business Operating Profit EUR4.61B

21 oct. 2024, 21:02 UTC

Achiziții, Fuziuni, Preluări

Sanofi Deal Jitters Imperil Stock's Big Rebound -- Barrons.com

21 oct. 2024, 08:52 UTC

Acțiuni populare

Stocks to Watch Monday: Boeing, Kenvue and Walmart -- WSJ

21 oct. 2024, 05:31 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Proposed Transaction Is Subject to Finalization of Agreements, Approvals

21 oct. 2024, 05:31 UTC

Achiziții, Fuziuni, Preluări

Sanofi Adjusts 2024 View After Opella Update

21 oct. 2024, 05:31 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Bpifrance Expected to Participate in Deal With 2% Stake in Opella

21 oct. 2024, 05:31 UTC

Achiziții, Fuziuni, Preluări

Sanofi Expects 2024 Business EPS to Grow by at Least Low-Single Digit Excluding Opella

21 oct. 2024, 05:31 UTC

Achiziții, Fuziuni, Preluări

Sanofi In Talks to Sell 50% Stake in Opella to CD&R

21 oct. 2024, 05:31 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Remain Significant Shareholder in Opella

21 oct. 2024, 05:31 UTC

Achiziții, Fuziuni, Preluări

Sanofi, CD&R Talks Value Opella at Enterprise Value of About EUR16B

21 oct. 2024, 05:31 UTC

Achiziții, Fuziuni, Preluări

Sanofi, CD&R in Exclusive Negotiations for Sale, Purchase of 50% Stake in Opella

16 oct. 2024, 10:33 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Sanofi Needs Clear Consumer Health Plan as Investors Concerns Mount -- Market Talk

Comparație

Modificare preț

Sanofi Așteptări

Obiectiv de preț

By TipRanks

22.02% sus

Prognoză pe 12 luni

Medie 65 USD 22.02%

Maxim 67 USD

Minim 63 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSanofi - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

3 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 3 analiști care au acordat evaluări ale acțiunilor Sanofi - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

52.98 / 53.66Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bullish.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Sanofi

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.